Product Information

TOBRAMYCIN-DEXAMETH OPHTH SUSP is a generic product labeled by Bausch & Lomb Incorporated, priced at $4.3672 per ML under NDC 24208029525. Its NADAC has been published 678 times since Nov 28, 2013.

FDA first approved this application on Oct 27, 1999. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

TOBRAMYCIN-DEXAMETH OPHTH SUSP

Tobramycin and Dexamethasone
$4.3672per ML

Strength

1; 3 mg/mL; mg/mL

NDC

24208029525

Classification

Generic

Dosage Form

SUSPENSION/ DROPS

Route

OPHTHALMIC

Effective Date

11/18/2026

Active Ingredients

DEXAMETHASONE; TOBRAMYCIN

Approval Type

Generic (ANDA)

FDA Application

ANDA064134

FDA Approved

10/27/1999

TE Code

AB

On Market Since

10/27/1999

Pharmacological Classes

Aminoglycoside Antibacterial
Aminoglycosides
Corticosteroid Hormone Receptor Agonists
Corticosteroid

Price Statistics

The NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has been published 678 times since Nov 28, 2013, and over the history we have for it it has declined 74.8%. The table below summarizes its recorded NADAC range and movement.

Current price$4.3672 per ML
All-time high$18.1894 (Jan 15, 2014)
All-time low$4.3419 (Oct 21, 2026)
52-week high$5.3173
52-week low$4.3419
Median price$14.8022
Average price$12.6455
Largest weekly change-44.9% (Jul 17, 2024)
Weeks tracked678
Tracking sinceNov 28, 2013

Price History

1W

+0.6%

1M

-4.4%

3M

-5.6%

6M

-17.9%

1Y

-12.4%

3Y

-42.5%

5Y

-70.4%

All

-74.8%

Generic Alternatives

The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 16% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of TOBRAMYCIN-DEXAMETH OPHTH SUSP?

The current National Average Drug Acquisition Cost (NADAC) for TOBRAMYCIN-DEXAMETH OPHTH SUSP, manufactured by Bausch & Lomb Incorporated, is $4.3672 per ML (NDC 24208029525), effective Nov 18, 2026.

How has the price of TOBRAMYCIN-DEXAMETH OPHTH SUSP changed over time?

Over the history we have for it, the NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has declined 74.8%. It has been tracked across 678 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for TOBRAMYCIN-DEXAMETH OPHTH SUSP?

Since Nov 28, 2013, the NADAC for TOBRAMYCIN-DEXAMETH OPHTH SUSP has ranged from a low of $4.3419 (Oct 21, 2026) to a high of $18.1894 (Jan 15, 2014), with a median of $14.8022 per ML.

Are there cheaper alternatives to TOBRAMYCIN-DEXAMETH OPHTH SUSP?

Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOBRAMYCIN-DEXAMETH OPHTH SUSP, is $3.6789 per ML — about 16% below TOBRAMYCIN-DEXAMETH OPHTH SUSP.

Who manufactures TOBRAMYCIN-DEXAMETH OPHTH SUSP?

TOBRAMYCIN-DEXAMETH OPHTH SUSP (NDC 24208029525) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a generic product.